Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Board of Directors of Phosagro recommended that dividends be paid for 2022

3/3/23 PHOR

Tesla ramped up production of electric cars in China in February

3/3/23 TSLA

Tinkoff Bank suspended currency transfers to Georgia

3/3/23 T

The volume of transactions in foreign stocks on SPCEX in February remained almost unchanged from January

3/3/23 SPBE

Grain transshipment volume of NKHP since the beginning of the agricultural year increased by 20.8%

3/3/23 NKHP

Yandex Bank increased its share capital by ₽250 million

3/3/23 YNDX

Rostelecom prepares to buy LeClick service

3/3/23 RTKM

Aeroflot will develop domestic air travel and tourism in the Krasnoyarsk region

3/3/23 AFLT

Fesco opened a subsidiary in Turkey

3/3/23 FESH

Sberbank issuing loans through the call center

3/3/23 SBER